LOS ANGELES, CA--(Marketwire - February 06, 2008) - Avantogen Oncology, Inc. (PINKSHEETS: AVTO) reports that SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) has announced that the first patient has been dosed in its phase 2 clinical trial using RP101. In addition, SciClone announced that RP101 has been granted Orphan Drug Designation for the adjunct treatment of pancreatic cancer by the U.S. Food and Drug Administration (FDA).
